北京天诺健成

TNJC Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics for metabolic and inflammatory diseases. The company focuses on high-value targets such as THR-beta, GLP-1R, and GIPR to address significant unmet medical needs in conditions like non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. Its lead candidate, TNJC06, is a highly selective THR-beta agonist currently in Phase 2 clinical trials. TNJC Biotech aims to provide potent, orally bioavailable alternatives to existing injectable treatments, leveraging a robust internal R&D engine. The company is backed by prominent venture capital firms and maintains a diverse pipeline of metabolic regulators.